NBN rs1800533: Understanding the p.Glu185Gln Variant
The rs1800533 variant is a common genetic change in the NBN gene, which encodes the nibrin protein involved in DNA repair. Researchers have extensively studied this variant to determine if it influences cancer susceptibility, though current evidence remains inconsistent and inconclusive.
What each genotype means
Common genetic profile
This is the most common genotype for this variant in many populations. Current clinical evidence classifies this specific change as benign, meaning it is not considered a cause of hereditary cancer syndromes.
This is the major allele genotype, found in the majority of individuals across most global populations.
Common genetic profile
This genotype represents a heterozygous state for the p.Glu185Gln variant. Clinical databases currently classify this variant as benign, and it is not considered a significant risk factor for cancer susceptibility.
Carried by a significant portion of the population, with a minor allele frequency of approximately 0.30 in European and East Asian cohorts.
Common genetic profile
This genotype represents a homozygous state for the p.Glu185Gln variant. Research indicates this variant is benign and does not contribute to the development of hereditary cancer-predisposing syndromes.
This genotype is less common than the heterozygous or homozygous reference states, occurring at frequencies consistent with the observed minor allele frequency of approximately 0.30.
What is rs1800533?
The variant rs1800533 is a single nucleotide polymorphism (SNP) located within the NBN gene. In genetic terms, this specific change results in a missense mutation, meaning it causes a single amino acid substitution in the resulting protein—specifically, replacing glutamic acid with glutamine at position 185 (p.Glu185Gln). Because this variant is found at a relatively high frequency in many populations, it is classified as a common polymorphism rather than a rare, highly penetrant mutation. Scientists track such variants to understand how subtle changes in protein structure might influence biological processes, such as the body's ability to maintain genomic stability over a lifetime.
The Role of the NBN Gene
The NBN gene provides instructions for making a protein called nibrin. This protein is a critical component of the MRN complex, a group of proteins that acts as a first responder to DNA damage. Specifically, the MRN complex identifies double-strand breaks in DNA and coordinates the necessary repair processes to prevent mutations from accumulating. When both copies of the NBN gene are non-functional, it leads to a rare, severe condition known as Nijmegen breakage syndrome, which is characterized by developmental issues and a high risk of cancer. Because of its central role in DNA repair, researchers have long hypothesized that even minor variations in NBN, such as rs1800533, might subtly alter the efficiency of these repair mechanisms, potentially impacting long-term health.
Research and Evidence Strength
The association between rs1800533 and cancer risk has been the subject of numerous studies over the past two decades. While some early, smaller studies suggested a potential link between this variant and an increased risk of various malignancies, larger meta-analyses and comprehensive reviews have failed to reach a consensus. The scientific community generally views the evidence for this specific variant as limited or inconclusive. Unlike rare, pathogenic mutations in NBN that are clearly linked to disease, rs1800533 does not show a strong, consistent effect across diverse populations. Consequently, it is not currently used in clinical settings to predict individual cancer risk or guide medical decision-making. The complexity of cancer genetics means that many factors, including environment and other genetic variants, likely play a larger role than any single common SNP.
Population Frequency
The rs1800533 variant is widely distributed across global populations. Data indicates that the minor allele frequency (MAF) is approximately 0.30 in both European and East Asian cohorts. This high frequency confirms that the variant is a common feature of the human genome rather than a rare anomaly. Because it is so prevalent, it is found in a large percentage of the healthy population, which further complicates efforts to link it to specific disease outcomes. When a variant is this common, it is difficult to isolate its individual contribution to health risks from the background noise of thousands of other genetic variations that every person carries.
What This Information Means for You
If you have received information about your rs1800533 genotype, it is important to understand that this result does not constitute a medical diagnosis or a definitive prediction of future health. Because the scientific evidence regarding this variant is inconsistent, it cannot be used to determine your personal risk for cancer. Genetic testing results should always be interpreted in the context of your personal and family medical history by a qualified healthcare professional or a genetic counselor. You should never make changes to your health management or screening schedule based on a single SNP result. If you have concerns about your cancer risk, discuss them with your doctor, who can provide guidance based on established clinical guidelines rather than individual genetic markers that lack definitive evidence.
How common is this variant?
The rs1800533 variant is common, with a minor allele frequency of approximately 0.30 in European and East Asian populations.
Frequently asked questions
Is rs1800533 a sign of Nijmegen breakage syndrome?
No. Nijmegen breakage syndrome is caused by rare, pathogenic mutations in both copies of the NBN gene. The rs1800533 variant is a common polymorphism and is not associated with this syndrome.
Should I be worried if I have the CC genotype for rs1800533?
No. The CC genotype is a common variation found in many healthy individuals. Current research does not support using this genotype to predict individual cancer risk.
Does this variant affect how I should be screened for cancer?
No. Clinical cancer screening guidelines are based on factors like age, family history, and personal health status. You should follow the screening recommendations provided by your healthcare provider.
Why do some studies say this variant is linked to cancer?
Early, small-scale studies sometimes report associations that are not replicated in larger, more rigorous studies. When looking at the total body of evidence, the link between rs1800533 and cancer remains inconclusive.
Sources & further reading
Educational information only, last refreshed 9/20/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1800533?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29